Durect

Durect reports Eladur phase II results in back pain

Wednesday, April 13, 2011

Durect has released results from a phase II clinical trial in chronic low back pain for Eladur (Transdurr-Bupivacaine), Durect’s investigational transdermal bupivacaine pain patch. This study was conducted by Durect’s collaborator, King Pharmaceuticals, which is now owned by Pfizer. In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between Eladur as compared to placebo was not met.  Complete data analysis is ongoing.

[Read More]

Durect reports Eladur phase II results in back pain

Tuesday, April 12, 2011

Durect has released results from a phase II clinical trial in chronic low back pain for Eladur (Transdurr-Bupivacaine), Durect’s investigational transdermal bupivacaine pain patch. This study was conducted by Durect’s collaborator, King Pharmaceuticals, which is now owned by Pfizer. In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between Eladur as compared to placebo was not met.  Complete data analysis is ongoing.

[Read More]